Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22156365 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2HSD11B1GAAKDM4EALDH1A1 | |
| SCHEMBL4550355 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2HSD11B1GAAKDM4EALDH1A1 | |
| SCHEMBL17831921 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2HSD11B1KDM4EALDH1A1PKM | |
| SCHEMBL20353652 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2HSD11B1GAAKDM4EALDH1A1 | |
| SCHEMBL26170625 | 0.72 | KMT2A (0.47) | KDM4EALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL12674136 | 0.72 | SMN1; SMN2 (0.60) | SMN1; SMN2HSD11B1GAAKDM4EALDH1A1 | |
| SCHEMBL20462329 | 0.71 | SMN1; SMN2 (0.50) | SMN1; SMN2HSD11B1KDM4EALDH1A1PKM | |
| SCHEMBL27812858 | 0.70 | SMN1; SMN2 (0.69) | SMN1; SMN2HSD11B1KDM4EMAPTKMT2A | |
| SCHEMBL25568039 | 0.70 | CCR5 (0.42) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL22156369 | 0.69 | SMN1; SMN2 (0.35) | SMN1; SMN2HSD11B1GAABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | SMN1; SMN2 989/4885HSD11B1 2562/4885GAA 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.